AC 104
Alternative Names: AC-104 - AbClon; AC104Latest Information Update: 04 Sep 2023
At a glance
- Originator AbClon
- Class Antibodies; Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 04 Sep 2023 Discontinued - Preclinical for Solid tumours in South Korea (unspecified route)
- 28 Jul 2020 No recent reports of development identified for preclinical development in Solid-tumours in South Korea
- 30 Jun 2016 Preclinical trials in Solid tumours in South Korea (unspecified route)